Related references
Note: Only part of the references are listed.Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Marco Ladetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling
N. C. Gutierrez et al.
LEUKEMIA (2010)
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Heinz Ludwig et al.
ONCOLOGIST (2010)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E. Terpos et al.
ANNALS OF ONCOLOGY (2009)
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Heinz Ludwig et al.
BLOOD (2009)
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
John Koreth et al.
BLOOD (2009)
Induction of angiogenesis by normal and malignant plasma cells
Dirk Hose et al.
BLOOD (2009)
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma
Marta Lionetti et al.
BLOOD (2009)
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
Antje Hoering et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Aldo M. Roccaro et al.
BLOOD (2009)
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
Sundar Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Prevention of infections and other complications after splenectomy
M. Engelhardt et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2009)
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Francesca Patriarca et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
Martina Kleber et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Evangelos Terpos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
'Light-chain escape-multiple myeloma'aEuroan escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring
A. Kuehnemund et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Relapse/Refractory Myeloma Patient: Potential Treatment Guidelines
Jesus F. San Miguel
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of autologous and allogeneic stem cell transplantation in myeloma
W. I. Bensinger
LEUKEMIA (2009)
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
A. Palumbo et al.
LEUKEMIA (2009)
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Jean-Luc Harousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
Benedetto Bruno et al.
SEMINARS IN HEMATOLOGY (2009)
Contents of Forthcoming Issues · Themenvorschau
Oncology Research and Treatment (2009)
Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors
Meletios A. Dimopoulos et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses
P. S. Haas et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
Donna E. Reece et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
S. Vincent Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E. Terpos et al.
LEUKEMIA (2008)
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
G. Schilling et al.
LEUKEMIA (2008)
Pathogenesis and treatment of renal failure in multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Flavia Pichiorri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study
Sylvia Feyler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Characterization of in vitro growth of multiple myeloma cells
Mihaela Zlei et al.
EXPERIMENTAL HEMATOLOGY (2007)
Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma:: Efficacy and clinical implications of tumor response kinetics
Laura Rosinol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
Martha Q. Lacy et al.
MAYO CLINIC PROCEEDINGS (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
Dennis Loeffler et al.
BLOOD (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)
Faith E. Davies et al.
HAEMATOLOGICA (2007)
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Pieter Sonneveld et al.
HAEMATOLOGICA (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Monitoring of renal function in cancer patients:: an ongoing challenge for clinical practice
M. Kleber et al.
ANNALS OF ONCOLOGY (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
Massimo Martino et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
Sara Prutchi-Sagiv et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
MicroRNA signatures in human cancers
George A. Calin et al.
NATURE REVIEWS CANCER (2006)
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model
Yuki Ishii et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients
Kostas Zervas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma
Mohamad A. Hussein et al.
MAYO CLINIC PROCEEDINGS (2006)
State of the art therapy in multiple myeloma and future perspectives
Ulrich Denz et al.
EUROPEAN JOURNAL OF CANCER (2006)
Systematic review: Bisphosphonates and osteonecrosis of the jaws
Sook-Bin Woo et al.
ANNALS OF INTERNAL MEDICINE (2006)
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma
BT Brinker et al.
CANCER (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients:: a single-centre analysis over a 12-year period
PS Haas et al.
ANNALS OF HEMATOLOGY (2006)
Guidelines on the diagnosis and management of multiple myeloma 2005
A Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma
M Wang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone - An emerging oral complication of supportive cancer therapy
CA Migliorati et al.
CANCER (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
Advances in biology of multiple myeloma: clinical applications
T Hideshima et al.
BLOOD (2004)
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant
AK Stewart et al.
CLINICAL CANCER RESEARCH (2004)
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome
R Zeiser et al.
BONE MARROW TRANSPLANTATION (2004)
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
A Palumbo et al.
BLOOD (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
MA Dimopoulos et al.
HEMATOLOGY JOURNAL (2004)
Strategies to improve the outcome of stem cell transplantation in multiple myeloma
L Catley et al.
HEMATOLOGY JOURNAL (2004)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma
H Einsele et al.
BONE MARROW TRANSPLANTATION (2003)
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
MH Kropff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
Transplantation salvage therapy for high-risk patients with myeloma in relapse
CK Lee et al.
BONE MARROW TRANSPLANTATION (2002)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
JD Rizzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
JR Berenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma
N Kröger et al.
BLOOD (2002)
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
JR Berenson et al.
BLOOD (2002)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)
Thalidomide and dexamethasone combination for refractory multiple myeloma
MA Dimopoulos et al.
ANNALS OF ONCOLOGY (2001)
Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation
M Engelhardt et al.
ANNALS OF HEMATOLOGY (2001)
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
KR Desikan et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
